Review papers by their claims

Evidence synthesis (claims & sources)

• lncRNA‑ATB: Overexpressed in keloids; knockdown reduces autocrine TGF‑β2 secretion via miR‑200c → ZNF217 regulation (human keloid fibroblasts; n=57). Methods: qRT‑PCR, ELISA, western blot, luciferase assays. Strength: mechanistic in vitro evidence but no in vivo causality shown lncRNA‑ATB mechanistic study
• HOXA11‑AS: Upregulated in keloids; knockdown reduces fibroblast proliferation, invasion, and glycolysis via miR‑205‑5p/FOXM1 axis (20 patient pairs). Supports lncRNA acting as miRNA sponge with downstream transcription factor effects; again, mostly in vitro HOXA11‑AS keloid paper
• lncRNA expression profiling: Differential lncRNA/mRNA expression between regressive vs mature scars (microarray, n=12) found hundreds of differentially expressed transcripts, indicating many lncRNAs may be disease-associated but requiring rigorous follow-up and validation lncRNA array in scars
• Broader molecular context: Keloid pathogenesis centers on dysregulated TGF‑β signaling, reduced inhibitory SMADs, myofibroblast persistence, hypoxia and mast cell interactions, and ECM overproduction — an environment where lncRNAs plausibly modulate transcriptional and post‑transcriptional networks SMAD6/7 reduced in keloids

Critical appraisal — strengths & limits

1. Strengths of the review's topic coverage: consolidates multiple primary studies that identify candidate lncRNAs with plausible molecular mechanisms (miRNA sponging, transcriptional regulation) and connects these to canonical fibrotic pathways (TGF‑β, FOXM1) lncRNA‑ATB evidence
2. Key limitations and blindspots:
   • Most mechanistic work is in vitro using primary keloid fibroblasts or cell lines — limited in vivo causality and missing longitudinal human data (onset vs progression).
   • Small sample sizes and single‑center sampling raise generalizability concerns and possible sampling bias (ethnicity, lesion site, chronicity) Small microarray cohort.
   • Publication bias: positive mechanistic findings (knockdown causes change) are over‑represented; negative or null lncRNA studies less likely published.
   • Functional redundancy and pleiotropy of lncRNAs complicate interpretation — knockdown effects may be off‑target or reflect broader transcriptome perturbation.
3. Potential confounders: tissue heterogeneity (fibroblast subtypes, immune infiltrates, mast cells, hypoxia), variation in fibroblast passage number and culture conditions, and lack of matched normal controls in some reports Mast cell‑fibroblast hypoxia study

Where the review could improve (specific, actionable)

• Quantify and tabulate primary-study sample sizes, ethnicity, lesion site, and whether matched controls were used (improves bias assessment).
• Distinguish in vitro mechanistic findings from in vivo/clinical evidence and score confidence per lncRNA (evidence pyramid).
• Recommend standardized experimental pipelines: paired tissue sampling, single‑cell RNA‑seq to map lncRNA cell-type specificity, and orthogonal validation (antisense oligonucleotides + xenograft or humanized skin models).

Concrete next experiments (testable & falsifiable)

1. Use antisense oligonucleotides (ASOs) against lncRNA‑ATB in patient‑derived keloid xenografts (immunodeficient mice with human skin grafts) to test whether systemic/local ASO reduces keloid size, collagen deposition, and TGF‑β2 levels — includes vehicle and scrambled controls; outcome: reduced keloid metrics would support causal role; absence would falsify it.
2. Single‑cell RNA‑seq of freshly excised keloid vs adjacent normal skin (n≥10 donors) to map lncRNA cell‑type specificity (fibroblast subclusters, immune cells, endothelial) and co-expression networks with TGF‑β pathway genes; reproducible cell-type localization would strengthen mechanistic claims.

Final verdict (concise)

The review correctly highlights lncRNAs as promising regulators in keloid fibrogenesis with plausible mechanisms (miRNA sponging, transcriptional regulation). Nonetheless, the field currently relies largely on moderately powered in vitro studies with limited in vivo validation. Stronger claims about therapeutic potential require larger, better‑controlled human cohorts and orthogonal in vivo tests.